DDInter1814 DDInter1658
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Tioguanine {u} (Compound) resembles {v} (Compound) Adenine
Tioguanine {u} (Compound) treats {v} (Disease) hematologic cancer
Tioguanine {u} (Compound) binds {v} (Gene) IMPDH2
Tioguanine {u} (Compound) causes {v} (Side Effect) Portal hypertension
Tioguanine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Tioguanine {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Tioguanine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Tioguanine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Tioguanine (Compound) resembles Adenine (Compound)
Tioguanine (Compound) treats hematologic cancer (Disease)
Tioguanine (Compound) binds IMPDH2 (Gene)
Tioguanine (Compound) causes Portal hypertension (Side Effect)
Tioguanine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab
Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Tioguanine may lead to a major life threatening interaction when taken with Cladribine
Tioguanine (Compound) resembles Mercaptopurine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine